Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Regenxbio Product RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio Product RGX-121 Achieves Primary Endpoint From Regenxbio ( RGNX ) we learned that results from the Phase I/II/III CAMPSIITE® trial of the firm’s product RGX-121 for the treatment of 5 years old patients diagnosed with Mucopolysaccharidosis Type II (...

February 9, 2024

Celularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment

Celularity Inc Celularity Inc. ( CELU ) announced the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer ( NK ) cell therapy, CYNK-001...

December 28, 2021

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit. See Also: CRISPR Therapeutics Advanced Steps

CRISPR Therapeutics Announcement Today, Feb. 15, 2024, CRISPR Therapeutics announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, Feb 21, 2024, at 1:00 p.m. ET. A live webcast of...

February 15, 2024

Vertex Pharmaceuticals Reports First Quarter 2024 Financial Results

Vertex Pharmaceuticals Vertex Pharmaceuticals ( VRTX ) reported consolidated financial 2024 results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex Pharmaceuticals said, “Vertex...

May 7, 2024

Why Intellia Therapeutics Acquisition of Rewrite Therapeutics Is Important

Intellia Therapeutics Acquires Rewrite Therapeutics The acquisition is, indeed good news. By acquiring Rewrite Therapeutics , Intellia Therapeutics ( NTLA ) has inherited a versatile DNA writing platform which enables a range of innovative genome editing strategies. The acquisition is...

February 7, 2022

An Important Milestone for Regenxbio Treatment of Wet AMD

Regenxbio Good News for wet AMD On January 10, 2022, Regenxbio Inc. ( RGNX ) announced the initiation of ASCENT, the second of two Phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in...

February 8, 2022

CRISPR Therapeutics Financial Results for Fourth Quarter and Full Year Ended December 31, 2023 Plus All You Need To Know About this Firm's Capabilities

CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics ( CRSP ) has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a...

February 22, 2024

Verrica Pharmaceuticals: Collaboration and License Agreements for the Treatment of Skin Diseases Other Than Molluscum Contagiosum

Verrica Pharmaceuticals Verrica Pharmaceuticals’ ( VRCA ) product YCANTH ( cantharidin ) is the only commercially available treatment approved by the FDA for the treatment of adults and pediatric patients two years of age and older with Molluscum Contagiosum. Molluscum...

May 16, 2024

Who Forgot About Enanta Pharmaceuticals?

Enanta Pharmaceuticals Expectations Expecting Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19 The Firm Completed Enrollment in RSVP, a Phase 2b Conducted Trial of EDP-938 in Adults With Community-Acquired...

February 11, 2022

Pivotal Data About Efficacy and Tolerability of Arcturus Therapeutics’ COVID-19 Vaccine Published in Nature Communications

Arcturus Therapeutics COVID-19 Vaccine Published CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics ( ARCT ) announced that Journal Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA)...

May 22, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024